Clinical review report : (AstraZeneca Canada Inc.) : indication : heart failure with reduced ejection fraction. Dapagliflozin (Forxiga) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

CADTH Common Drug Review

Language:

English

Subjects (All):

Heart failure--Treatment.

Heart failure.

Physical Description:

1 online resource (81 pages) : illustrations.

Edition:

Version: Final (with redactions).

Place of Publication:

Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2021.

Summary:

The objective of this report is to perform a systematic review of the beneficial and harmful effects of dapagliflozin 5 mg and 10 mg tablets for the treatment of heart failure with reduced ejection fraction in adults.

Contents:

Abbreviations

Executive Summary

Introduction

Stakeholder Engagement

Clinical Evidence

Conclusions

Disease Background

Standards of Therapy

Drug

Patient Group Input

Clinician Input

Systematic Review (Pivotal and Protocol Selected Studies)

Findings From the Literature

Results

Indirect Evidence

Other Relevant Evidence

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Literature Search Strategy

Appendix 2. Excluded Studies

Appendix 3. Detailed Outcome Data

Appendix 4. Description and Appraisal of Outcome Measures

References.

Notes:

Includes bibliographical references.

Description based on publisher supplied metadata and other sources.